ReviewPediatric radiology2018
Hepatocyte-specific contrast media: not so simple.
Review in Pediatric radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 18 citations in OpenAlex.
- Contrast enhanced ultrasound of liver lesions in patients treated for childhood malignancies.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Fontan-associated liver disease: Diagnosis, surveillance, and management.Frontiers in pediatrics · 2023Review
- Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.Abdominal radiology (New York) · 2021Review
- Gd-EOB-DTPA MRI for focal nodular hyperplasia-like lesions in pediatric cancer survivors.European radiology · 2021Article
- Robotic resection of liver focal nodal hyperplasia guided by indocyanine green fluorescence imaging: A preliminary analysis of 23 cases.World journal of gastrointestinal oncology · 2020Article
- Congenital Portosystemic Shunts in Children: Associations, Complications, and Outcomes.Digestive diseases and sciences · 2020Article
- Intravenous gadolinium-based hepatocyte-specific contrast agents (HSCAs) for contrast-enhanced liver magnetic resonance imaging in pediatric patients: what the radiologist should know.Pediatric radiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocyte-specific contrast media are gadolinium chelates that are taken up by hepatocytes and partially cleared via the biliary tree. The absence of lesional uptake of the contrast media in the hepatobiliary phase is a marker of either the absence of hepatocytes or of poorly functioning, neoplastic hepatocytes. Uptake of the contrast media in the hepatobiliary phase, whether equal to or greater than background liver, reflects the presence of hepatocytes but does not equate to absence of neoplasia. Accurate diagnosis of liver lesions utilizing hepatocyte-specific contrast media requires an understanding of the mechanisms of uptake and clearance of the contrast media to avoid misdiagnosis. In this review we discuss the mechanisms of hepatocellular transport of hepatocyte-specific contrast media and utilize an understanding of those mechanisms to discuss the imaging appearance of a subset of hepatocellular lesions that can be seen in the pediatric and young adult liver. We pay particular attention to lesions that appear iso- to hyperintense in the hepatobiliary phase but have the potential for adverse clinical outcomes. We also discuss strategies for identifying these lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.